News
Lake Street Maintains Buy on OptiNose, Raises Price Target to $4
18 Mar 24
News, Price Target, Analyst Ratings
12 Health Care Stocks Moving In Friday's After-Market Session
15 Mar 24
Movers
HC Wainwright & Co. Initiates Coverage On OptiNose with Buy Rating, Announces Price Target of $5
11 Mar 24
News, Price Target, Initiation, Analyst Ratings
OptiNose Q4 GAAP EPS $(0.09), Inline, Sales $19.86M Beat $19.23M Estimate
7 Mar 24
Earnings, News
Earnings Scheduled For March 7, 2024
7 Mar 24
Earnings
OptiNose's Earnings: A Preview
6 Mar 24
Earnings
Optinose Announces The Publication Of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE In The Journal Of Allergy And Clinical Immunology: In Practice
18 Jan 24
Biotech, News, General
Press releases
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
15 Mar 24
Press Releases, General
Thinking about buying stock in CXApp, CCSC Technology International, Vroom, Spero Therapeutics, or OptiNose?
14 Mar 24
Small Cap, Opinion, Press Releases
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
7 Mar 24
Earnings, Press Releases
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
29 Feb 24
Press Releases
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
18 Jan 24
Press Releases, General